About 400,000 Swedish men aged 50-80 years suffer from benign prostate problems, and half of them will require treatment. In a recent survey performed by Netdoktor, the daily lives of almost half (49%) of the respondents are governed by finding the nearest toilet. They need to get up at night, and hunt for toilets in the daytime. The survey was commission by ProstaLund.

The primary cause of men seeking medical help is anxiety about their prostate problems. Unfortunately, the doctor does not always share their concern. Despite the availability of several different treatment methods to cure prostate problems, about 50 percent of the respondents’ doctors consider that it is something “related to age – wait and see”, and leave the patient and his ailment without treatment. This also leaves patients with a nagging worry that their problem could nonetheless be prostate cancer – which it does not need to be.

Poorer quality of life

40 percent of the respondents get up between two and five times each night. BPH (Benign Prostatic Hyperplasia) also affects the partner negatively in the form of disturbed sleep and diminished sex life. As many as 46 percent say that their sleep is disrupted sometimes or the whole time. Half also think that their sex life is affected negatively by prostate problems. More men consider today that their quality of life is poorer in conjunction with their prostate troubles. In a survey performed in 2004, about 20 percent of men experienced an impaired quality of life. Today, the figure is 34 percent who feel that their quality of life has deteriorated. For example, they avoid playing sports, travelling or going out to a restaurant.

Improved reception

The survey also showed the aspects that patients miss in their contact with the doctor: effective treatment, more information about different treatments – advantages and disadvantages, taking problems sincerely, and being received well and taken seriously.

Waiting times

The Swedish Association of Local Authorities and Regions (SKL) has a website (vantetider.se) that indicates the length of waiting times for treatment within urology. Most clinics in Sweden currently have at least 13 weeks’ waiting time. ./.

For further information, please contact:

Ann Baron, Marketing Manager, +46 (0)70-744 44 80.
ann.baron@prostalund.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it

The majority of men over 50 years old will suffer from Benign Prostate Hyperplasia (BPH) with a quarter, 25 %, of them needing some form of medical or surgical treatment. ProstaLund has extended its product portfolio in order to improve accessibility to CoreTherm both nationally and internationally.

ProstaLund has developed a new appliance for the treatment of prostate glands with a smaller degree of enlargement. The new appliance is designed to be used when the enlarged prostate has a weight of 20 to 50 grams. Prostate weight is normally estimated to be about 20 grams – although depending on how the gland has grown, minor enlargement can also create the same troublesome symptoms as a significantly more enlarged prostate.

The new appliance is based on the Company’s well-established and documented CoreTherm treatment system and is composed of a new treatment catheter, microwave antenna and temperature probes that are all adapted to operate effectively on smaller prostate glands.

The new appliance is CE-labelled and approved for sale within the EU.

“We believe that the potential underlying volume of patients where CoreTherm is a suitable treatment option is increasing by about 10-15 percent. We perceive it as a further strength to now be able to offer our clients a treatment option that embraces a broader spectrum – thus enabling us to standardize the treatment of BPH to CoreTherm. Our objective is now to have the new appliance approved in other countries where CoreTherm has already been approved by requisite authorities and is used clinically,” says Ulf Rosén, CEO of ProstaLund.

He continues by saying: “The United States is a prioritized market and our application for approval of the short appliance has also been submitted to the CDRH/FDA. We are now awaiting their independent evaluation of our documentation.”

For further information, please contact:

Ulf Rosén, President & CEO, +46 (0)706-86 29 16.
ulf.rosen@prostalund.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it
ProstaLund® operates within the medical technology sector. The Company develops and markets equipment for the treatment of benign prostate enlargement based on patented individually adapted microwave treatment. The procedure is carried out with local anaesthetic with results comparable to those of surgery requiring several days’ hospitalization. Over 20,000 men have undergone treatment with CoreTherm® and the method is currently used at more than 200 hospitals and surgical centres in the United States and Europe. www.prostalund.com